NCT06527300
A Multicenter, Open-label, Single-arm, Phase II Study of NHWD-870 HCl in Adults and Adolescents With Advanced NUT Cancer
StatusRecruiting
PhasePhase 2
Primary completion (estimated)
At risk: Primary completion moved 1 year 9 months later.
See at-risk trials from Zhejiang Wenda Pharma Technology LTD.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Jun 30, 2025 to Mar 30, 2027 Show 4 more changesShow less
- Eligibility criteria expanded, about 16 words
- Trial status changed: Unknown → Recruiting
- Enrollment increased: 48 → 68 participants
- Study completion pushed from Dec 30, 2025 to Aug 30, 2027
- Minor Changed Registry marked status Unknown; last known: Recruiting
- Minor Trial status: Recruiting to Unknownv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Objective response rate (ORR)
Timeframe: Completed at least four weeks of treatment, the curative effect evaluation of CR, PR and maintain at least 4 weeks, the proportion of the subjects,up to 5 months;
Secondary (4)
Duration of response (DoR)
Disease control rate (DCR)
Progression-free survival (PFS)
time to remission (TTR)
Arms and interventions
Adult:NHWD-870 HCl 2mg ; Adolescent:NHWD-870 HCl 1.5mg/2mgExperimental
Take a fixed dose of NHWD-870 HCl tablets orally.
Drugs: NHWD-870 HCl
Sites
1 site in 1 country
- Three Gorges Hospital Affiliated to Chongqing UniversityChongqing, China